Credits: Canva
The world that we live in is filled with sounds, some are comforting and some could be jarring too. But what if the constant noise surrounding us is doing us more harm than we realize? There has been immense research that shows that noise is not just a nuisance, but a silent killer and affects our health in ways we do not even know. There are associations of sound causing heart attacks, type 2 diabetes, and dementia.
Noise is seen as an annoyance, but it effects can go beyond what we imagine. When we hear a sound, it travels through the ear to the brain. This is where it gets processed by the amygdala. It is a region that is responsible for emotional responses. This also triggers a stress response- our heart rate increases, our blood pressure rises, and stress hormones like cortisol flood our system.
This response is also designed to help us react to immediate threats. Especially, if we hear the sound of a predator approaching. However, when we are exposed to constant noise, this response is triggered repeatedly and could compel us to live in a long-term anxious state.
Many studies including Harvard Health and theAmerican College of Cardiology have found associations of noise with health problems including putting a person at a higher risk of cardiovascular diseases such as heart strokes, attacks, and high blood pressure. The constant activation of the stress response can take a toll on the body, increasing inflammation and making it harder for the heart and circulatory system to function properly. Over time, this can lead to serious health conditions like heart disease and diabetes.
Even more troubling, research suggests that noise pollution may contribute to mental health issues. Studies have found a strong connection between exposure to noise and disturbed sleep, which in turn can cause anxiety, depression, and cognitive decline. The World Health Organization estimates that noise contributes to around 12,000 premature deaths annually across Europe alone. This invisible threat, however, is often overlooked because the effects are gradual and cumulative.
One of the most insidious aspects of noise pollution is its impact on sleep. Even when we are asleep, our bodies are not fully immune to the effects of sound. Our ears never fully “turn off,” meaning that even faint noises can disrupt our sleep cycle. Research has shown that people who live in noisy environments—whether near busy roads, airports, or urban centers—often experience fragmented sleep, leading to fatigue and a weakened immune system. Over time, this chronic lack of restful sleep can lead to significant health problems, including an increased risk of developing cognitive disorders such as dementia.
As cities continue to grow, noise pollution is becoming more widespread. Traffic noise, in particular, is one of the most common and harmful sources. The rise of urbanization means more cars, buses, and trains, all of which contribute to an ever-increasing din. This urban soundscape is often relentless, with little respite for those living within it. In densely populated cities, people are exposed to high decibel levels, which can exceed safe thresholds for heart health. In many cases, the sheer volume of sound is not just unpleasant; it’s dangerous.
The solution is not as simple as reducing noise in our immediate surroundings, though efforts to reduce traffic noise and limit industrial sounds are essential. Some cities have taken steps to create quieter spaces by converting busy roads into pedestrian zones or installing noise barriers. These measures have shown to have a positive impact on public health, with research suggesting that even small reductions in noise can prevent premature deaths and improve overall well-being.
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously called fatty liver disease, is becoming extremely common in people with type 2 diabetes in India.
Studies suggest that 50–70 percent of Indians with type 2 diabetes may have fatty liver, and a significant proportion can progress to inflammation, liver fibrosis, cirrhosis, or even liver cancer if the condition is not detected early. Because India already has one of the world’s largest populations with diabetes, MASLD is emerging as a major but under-recognized public health problem.
The recently published consensus guidelines developed by Indian experts aim to provide practical, India-specific recommendations for diagnosing and managing MASLD in people with type 2 diabetes.
In fact, these are the first global guidelines for MASLD and type 2 diabetes, albeit restricted to India. This matters because most existing international guidance—including from organizations such as the American Diabetes Association—is largely based on evidence and healthcare systems in high-income Western countries. These recommendations often assume easy access to expensive diagnostic tests and medications, which may not always be feasible in India.
In India, healthcare costs are frequently paid out-of-pocket by patients. Advanced imaging tests or newer medications can therefore be unaffordable for many people.
The Indian consensus addresses this reality by recommending step-wise and cost-effective screening strategies, beginning with simple clinical risk assessment and basic laboratory tests, followed by non-invasive fibrosis scoring tools and ultrasound when appropriate. This approach helps identify high-risk individuals without overburdening patients or the healthcare system.
Another important reason these guidelines matter is that Asian Indians have a unique metabolic profile. Compared with Western populations, Indians often develop diabetes and fatty liver at younger ages and lower body weight, partly because of higher abdominal fat and insulin resistance. Therefore, early screening for liver disease in people with diabetes becomes particularly important in India.
Dietary recommendations are also adapted to local eating patterns. Instead of focusing on Western dietary models, the guidelines emphasize reducing refined carbohydrates, excess sugars, and unhealthy fats common in Indian diets while promoting traditional, healthier foods, whole grains, legumes, and increased physical activity.
In simple terms, these India-specific guidelines aim to ensure that more patients with diabetes are screened early, treated appropriately, and protected from severe liver complications, using strategies that are practical, affordable, and suited to the realities of the Indian healthcare system.
Guidelines for MASLD developed in Western countries provide important scientific guidance, but they are often designed for healthcare systems with greater resources and different patient characteristics. The Indian consensus recommendations differ in several key ways to make them more suitable for local populations and healthcare settings.
First, screening strategies are more pragmatic and cost-conscious. Western guidelines often recommend advanced imaging tests or specialized biomarkers to assess liver fat and fibrosis. However, these tests can be expensive and not widely available in many parts of India.
The Indian recommendations emphasize simple, widely available tools—such as routine blood tests and non-invasive fibrosis scoring systems—before considering more advanced imaging. This stepwise approach ensures that patients who are most at risk are identified while keeping costs manageable.
Second, the guidelines recognize the unique metabolic risk profile of Asian Indians. Compared with Western populations, Indians tend to develop metabolic diseases such as type 2 diabetes and fatty liver at younger ages and lower body mass index (BMI). Abdominal obesity and insulin resistance are particularly common.
Therefore, the Indian recommendations stress earlier and more vigilant screening for MASLD in people with diabetes, even if they are not severely obese.
Third, treatment priorities differ because of affordability and access to medications. Western guidelines may emphasize newer and often expensive drugs that show benefits for fatty liver disease. While these therapies can be effective, they may not be accessible to many patients in low- and middle-income countries.
The Indian consensus places stronger emphasis on lifestyle interventions, weight reduction, improved diet, and physical activity as the foundation of treatment, while suggesting pharmacotherapy selectively based on evidence, availability, and cost.
Fourth, perhaps the most important difference, dietary advice is culturally tailored. Western guidelines typically discuss Mediterranean-style diets.
In contrast, the Indian recommendations translate healthy eating principles into Indian dietary patterns, focusing on reducing refined carbohydrates, sugar-sweetened foods, and excess saturated fats while promoting whole grains, pulses, vegetables, and traditional balanced meals.
Finally, the Indian document highlights the need for public health awareness and primary care involvement, since a large proportion of patients with diabetes are managed outside specialized centers.
Overall, the key difference is that while Western guidelines provide strong scientific foundations, the Indian recommendations adapt those principles to local realities.
Credits: Wikimedia Commons and Instagram
Bristol Palin, an American real estate agent, who was a former public speaker and reality television personality started experiencing facial paralysis over a tear ago. On March 9, her 35-year-old daughter Sarah Palin posted a video on her Instagram Stories that shared an update on her ongoing health struggles. The story revealed that she is now considering plastic surgery to fix her paralysis.
"I am going to have a consultation today with a plastic surgeon in Austin," she said. "I have read that she specializes in facial paralysis type stuff so we will see what she says."
She also said, "Prayers because maybe she can help mostly with this eye," while pointing to her left eye. "When I smile or when I am expressive, it closes. I don't really care about my crooked mouth but my eye...so embarrassing to me. I feel like I should wear an eyepatch or something."
She went on to say, "It looks crazy and I just feel like I cannot even smile because it just closes. So maybe she can do some Botox or maybe there is some options with surgery. So we will see. Maybe she ca help with this eye or just the overall symmetry."
She also said that she had just returned from Alaska, where she visited another specialist who does her facial nerve blocks to help her paralysis. She also posted another update on her Instagram Stories and said that her consultation went well and that she will be sharing the information with her followers soon.
It was in January 2025, when she revealed her facial paralysis on Instagram. "I woke up nine days ago with a little weird sensation in my face. My mouth was pulling this way and it just felt a little off. So I went, looked in the mirror. I'm like 'Wow. This is looking a little weird. I feel like everything is pulling to the left."
She said that hours later her condition got worse and the left side of her face was having a "delayed" reaction.
Read: Why Does Your BBL Smell? Doctor Explains 4 Reasons That Could Cause It
As per a 2020 study published in the Indian Journal of Plastic Surgery, botulinum toxin (Botox) injections are helpful and are minimally invasive technique to restore facial symmetry. However, the study noted that a "surprisingly small minority of aesthetic injectors treat this condition."

The study also gives a case study of a patient with longstanding facial nerve paralysis after resection of an osteogenic sarcoma, before and after two weeks after first treatment with botulinum toxin. The improvements could be seen in mentalis synkinesis, more symmetrical smile, and improved eye apertures on animation.
It is an FDA-approved, injectable neurotoxin derived from Clostridium botulinum bacteria. It temporarily relaxes muscles by blocking nerve signals, commonly used to smooth dynamic wrinkles and treat medical conditions like chronic migraines, excessive sweating, and muscle spasms. Its effects last from three to four months.
Botox prevents the release of a neurotransmitter that signals muscles to contract, causing them to relax and soften wrinkles. Results typically appear in 3 to 14 days.
Credits: Canva and iStock
The US Food and Drug Administration approved leucovorin for cerebral folate deficiency in the receptor 1 gene, a rare genetic condition. However, last year, in September, this drug was noted as the possible and potential treatment for children with autism. The Trump administration noted that Tylenol may be triggering autism in children when is consumed by pregnant mothers. The same conference touted this drug as a potential treatment, while not enough scientific evidence was there to support the claim. Yet, many parents looked for the prescription to support their children.
Health and Me also reported a story of a mother who looked for the drug for her three-year-old son. Another case of four-year-old Jose Morales-Ortiz, who struggled to speak even two-word sentences. As per a CNN report, he was diagnosed with severe autism and rarely responded when someone called his name.
However, something changed, in early summers, he began telling his guardian Keith Joyce about the conversation with his classmates and answering follow-up questions. For Keith, it was a moment of joy. It was also the first time Keith had a conversation with him.
Joyce believes the change began after Jose started taking leucovorin, a medication originally approved to reduce the side effects of certain chemotherapy drugs. Now, researchers are investigating whether the drug may help some children with autism—particularly those with a condition known as cerebral folate deficiency.
However, scientists caution that while early studies are promising, the evidence is still limited and the treatment remains controversial.
Leucovorin, also known as folinic acid, is a biologically active form of vitamin B9 or folate. Unlike standard folic acid supplements, it does not require the body to convert it into an active form before it can be used. Due to this very feature, it can bypass certain metabolic steps and deliver folate more directly to the cells.
It is a high-dose B vitamin, which is commonly used as a treatment to counteract the side effects of chemotherapy. It has been approved by the FDA for cerebral folate deficiency in the receptor 1 gene. The disease is rare and fewer than 50 cases have been identified worldwide. FDA Commissioner Dr Marty Makary called this approval "a significant milestone" for patients with the condition.
Doctors have used the drug for several purposes, which also include:
Recently, scientists began exploring whether leucovorin could also help certain neurological conditions.
Read: Leucovorin Approved By FDA But For A Rare Genetic Disease, Not For Autism
Folate is essential for brain development and neural function.
It helps in:
During pregnancy, folate is so critical that many countries fortify foods with folic acid to prevent birth defects such as neural tube defects.
However, in some children, the issue may not be a lack of folate in the diet—but a problem with how folate reaches the brain.
In 2005, researchers discovered an unusual phenomenon in some children with developmental disorders.
Although their blood folate levels were normal, their brain folate levels were extremely low.
The reason appeared to be autoantibodies—immune proteins that mistakenly attack the body’s own tissues. In this case, the antibodies targeted folate receptor alpha, the protein responsible for transporting folate across the blood-brain barrier.
This condition is called cerebral folate deficiency.
Researchers also developed a diagnostic blood test called the Folate Receptor Autoantibody Test (FRAT) to detect these antibodies.
It could work in such a case because it is able to bypass the blocked folate receptors. It does not rely on the usual transport system and is able to enter the brain through alternative transport pathways, which allow neurons to access the folate they need. Scientists also believe that this could improve neurotransmitter production, support neural communication, and enhance brain metabolism in certain children.
Some clinical studies have suggested that leucovorin may improve language and communication skills in certain children with autism.
However, the results have been mixed.
Some studies have found only modest improvements, and large placebo-controlled trials—considered the gold standard in medical research—are still lacking.
Because autism is a complex spectrum condition with many biological pathways involved, researchers emphasize that no single medication is likely to work for every child.
The growing interest in leucovorin reflects a broader shift in autism research: looking for biological subtypes of the condition that might respond to targeted treatments.
If cerebral folate deficiency proves to be one of those subtypes, leucovorin could become an important therapy for a specific group of children.
But scientists emphasize that autism is highly complex. “There’s no autism pill,” many researchers say.
© 2024 Bennett, Coleman & Company Limited